Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 17.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Males or females with a confirmed diagnosis of and documented history of relapsed or refractory malignant disease (B-cell lymphoma and/or CLL) for which no therapy of curative or high priority exists and for whom treatment with a Btk inhibitor may be deemed appropriate.~2. Age ≥ 18 years.~3. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.~Key Exclusion Criteria:~1. Central nervous system (CNS) lymphoma.~2. Women who are pregnant or lactating.~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tirabrutinib 20 mg Once Daily (CLL) (Type: EXPERIMENTAL): Participants with relapsed/refractory chronic lymphocytic leukaemia (CLL) received tirabrutinib 20 mg once daily.
- Tirabrutinib 40 mg Once Daily (CLL) (Type: EXPERIMENTAL): Participants with relapsed/refractory CLL received tirabrutinib 40 mg once daily.
- Tirabrutinib 80 mg Once Daily (CLL) (Type: EXPERIMENTAL): Participants with relapsed/refractory CLL received tirabrutinib 80 mg once daily.
- Tirabrutinib 160 mg Once Daily (CLL) (Type: EXPERIMENTAL): Participants with relapsed/refractory CLL received tirabrutinib 160 mg once daily.
- Tirabrutinib 320 mg Once Daily (CLL) (Type: EXPERIMENTAL): Participants with relapsed/refractory CLL received tirabrutinib 320 mg once daily.
- Tirabrutinib 400 mg Once Daily (CLL) (Type: EXPERIMENTAL): Participants with relapsed/refractory CLL received tirabrutinib 400 mg once daily.
- Tirabrutinib 500 mg Once Daily (CLL) (Type: EXPERIMENTAL): Participants with relapsed/refractory CLL received tirabrutinib 500 mg once daily.
- Tirabrutinib 600 mg Once Daily (CLL) (Type: EXPERIMENTAL): Participants with relapsed/refractory CLL received tirabrutinib 600 mg once daily.
- Tirabrutinib 300 mg Twice Daily (CLL) (Type: EXPERIMENTAL): Participants with relapsed/refractory CLL received tirabrutinib 300 mg twice daily.
- Tirabrutinib 20 mg Once Daily (NHL) (Type: EXPERIMENTAL): Participants with relapsed/refractory non-Hodgkin's lymphoma (NHL) received tirabrutinib 20 mg once daily.
- Tirabrutinib 40 mg Once Daily (NHL) (Type: EXPERIMENTAL): Participants with relapsed/refractory NHL received tirabrutinib 40 mg once daily.
- Tirabrutinib 80 mg Once Daily (NHL) (Type: EXPERIMENTAL): Participants with relapsed/refractory NHL received tirabrutinib 80 mg once daily.
- Tirabrutinib 160 mg Once Daily (NHL) (Type: EXPERIMENTAL): Participants with relapsed/refractory NHL received tirabrutinib 160 mg once daily.
- Tirabrutinib 320 mg Once Daily (NHL) (Type: EXPERIMENTAL): Participants with relapsed/refractory NHL received tirabrutinib 320 mg once daily.
- Tirabrutinib 480 mg Once Daily (NHL) (Type: EXPERIMENTAL): Participants with relapsed/refractory NHL received tirabrutinib 480 mg once daily.
- Tirabrutinib 600 mg Once Daily (NHL) (Type: EXPERIMENTAL): Participants with relapsed/refractory NHL received tirabrutinib 600 mg once daily.
- Tirabrutinib 240 mg Twice Daily (NHL) (Type: EXPERIMENTAL): Participants with relapsed/refractory NHL received tirabrutinib 240 mg twice daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete